Here’s an article detailing the HistoSonics news, written in a polite tone and in English:
HistoSonics Expands Insurance Coverage for Non-Invasive Liver Tumor Treatment to 7 Million Highmark Blue Cross Blue Shield Members
[City, State] – [Date] – HistoSonics, a pioneering medical technology company revolutionizing cancer therapy, is pleased to announce a significant expansion of insurance coverage for its innovative, non-invasive liver tumor treatment. Highmark Blue Cross Blue Shield, a major health insurance provider, will now offer coverage for HistoSonics’ Therapy System to an estimated 7 million of its members. This development marks a crucial step in increasing patient access to a cutting-edge treatment option for liver tumors.
The HistoSonics Therapy System utilizes proprietary histotripsy technology, a non-invasive method that employs focused ultrasound waves to mechanically destroy targeted tumor tissue. This approach offers a compelling alternative to traditional treatments, potentially reducing side effects and improving patient recovery times without the need for incisions or radiation.
The expanded coverage from Highmark Blue Cross Blue Shield is a testament to the growing clinical evidence and recognition of the HistoSonics Therapy System’s efficacy and patient benefits. This decision will empower a substantial number of patients with liver tumors within Highmark’s network to explore and access this advanced therapeutic option.
“We are delighted to partner with Highmark Blue Cross Blue Shield to bring the benefits of our Therapy System to a much larger patient population,” said [Name and Title of a HistoSonics Spokesperson, if available, otherwise state ‘a representative from HistoSonics’]. “Our mission is to provide more effective and patient-friendly cancer treatments, and this expanded coverage is a vital achievement in making our technology accessible to those who need it most.”
This advancement is particularly significant for individuals diagnosed with primary and secondary liver tumors, offering them a potentially less burdensome treatment pathway. The ability to cover this treatment through insurance will alleviate financial barriers for many patients, enabling them to make informed decisions about their care.
The HistoSonics Therapy System is designed to be delivered in an outpatient setting, further enhancing its appeal as a patient-centric treatment. By providing a non-invasive solution, HistoSonics aims to redefine the standard of care for liver cancer treatment, prioritizing patient well-being and quality of life.
This collaboration with Highmark Blue Cross Blue Shield underscores the healthcare industry’s increasing embrace of innovative medical technologies that demonstrate both clinical superiority and economic value. HistoSonics remains committed to advancing its technology and expanding access to its life-changing therapies for cancer patients worldwide.
AI has delivered the news.
The answer to the following question is obtained from Google Gemini.
Business Wire French Language News published ‘HistoSonics étend la prise en charge par assurance du traitement non invasif des tumeurs hépatiques à 7 millions d’assurés Blue Cross Blue Shield d’Highmark’ at 2025-07-15 03:50. Please write a detailed article about this news in a polite tone with relevant information. Please reply in English with the article only.